WuXi NextCODE announced as Clinical Interpretation Partner for 100,000 Genomes Project.

WuXi NextCODE’s analysis platform continues to be in high demand among large-scale genome projects. Today Genomics England have announced that the company has been contracted as a Clinical Interpretation Partner for the 100,000 Genomes Project, taking charge of data interpretation for cancer and rare disease samples. 

“We are delighted to be working with WuXi NextCODE,” said Dr Augusto Rendon, Director of Bioinformatics at Genomics England. “Their sequence analysis platform will help us to return high quality variant interpretation results back to clinicians and make a direct impact on patient care.”

The Project aims to sequence 100,000 while genomes from approximately 70,000 NHS patients and their families. Ultimately the aim is to make genomic medicine a core service of the NHS, driving the development of personalised care for patients. During the study patients may get a diagnosis of their condition for the first time, or get a better idea of the treatments that will be most effective for them. 

Hannes Smarason, President and COO of WuXi NextCODE, said: “We are very pleased to be playing a central role in a project that is a driving force for precision medicine worldwide. We look forward to putting our technology to work for NHS patients through interpretation and by applying the knowledge gained to advance the development of targeted new therapies for cancer and a range of rare conditions.”

More on these topics